Lisa Kahn

Lisa Kahn has extensive experience in regulatory affairs, particularly in the areas of chemistry, manufacturing, and controls (CMC) within the pharmaceuticals industry. Currently serving as the Director of Regulatory Affairs CMC Biologics at Eisai US since May 2019, Lisa has previously held significant roles such as Director of Regulatory Affairs Innovative Science at Glenmark Pharmaceuticals and Associate Director of Regulatory Affairs CMC for Cell and Gene Therapy at Novartis Pharmaceuticals. Additional experience includes positions at Dendreon and Genzyme, which encompassed various levels of regulatory responsibilities from director to senior manager. Lisa Kahn earned a BS in Biology and Medical Technology from Felician University and furthered education at Seton Hall University.